Dornase alfa for respiratory insufficiency

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Jul 2020: Trial registered, NCT04488081
  2. 31 Jul 2020: Trial started, NCT04488081

The trials

NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

State
Under way
Phase
Phase 2
People
1,500 planned
Started
31 Jul 2020
Primary completion
31 Jul 2028
Arms
Dornase + Standard of Care (CLOSED)
Results
None posted
  1. 27 Jul 2020: Trial registered
  2. 31 Jul 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Pulmozyme.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.